Shanghai Cell Therapy Group
PrivateLast Round
Series D
Dec 6, 2021
Est. Valuation
$1.12B
Total Funding Raised
$278.33M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Shanghai Cell Therapy Group operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series D round in December 2021.
Shanghai Cell Therapy Group is a biotechnology company that develops cell therapy products and provides related services for cancer and age-related diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2C
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Shanghai Cell Therapy Group Comparables
Compare Shanghai Cell Therapy Group with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vcanbio Cell & Gene Engineering Corporation | 75% | |
| Hebei Union Stem Cell Co., Ltd. | 75% | |
| Sichuan Neo-Life Stem Cell Biotech Inc. | 72% |
For institutional investors. Book with your work email.
Shanghai Cell Therapy Group Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Dec 6, 2021 | ||||
| Series D | Mar 23, 2021 | ||||
| Series C | Dec 17, 2018 | ||||
| Series B | Apr 19, 2016 | ||||
| Series A | Jun 3, 2014 |
For institutional investors. Book with your work email.
Shanghai Cell Therapy Group Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GF Xinde Investment Management | Series D |
| Legend Capital | Series C, Series B |
| CCB International | Series D |
| 怀格资本 | Series D |
| Jiuzhou Venture | Series D |
| China Industrial Asset Management Limited | Series C |
| Haier Capital | Series D, Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 29, 2026
Monthly visitors increased 469% MoM, reaching 9.2K.
- Jul 20, 2026
Open roles increased to 28, 2.2x the trailing average.
For institutional investors. Book with your work email.
Shanghai Cell Therapy Group Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Shanghai Cell Therapy Group's valuation, stock price, and market status.
Is Shanghai Cell Therapy Group a public or private company?
Shanghai Cell Therapy Group is a private company.
What is the current stock price of Shanghai Cell Therapy Group?
Shanghai Cell Therapy Group is a private company, so its shares have no public market price. Caplight tracks Shanghai Cell Therapy Group's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Shanghai Cell Therapy Group worth (valuation)?
Shanghai Cell Therapy Group's valuation is estimated at $1.1B based on funding round data.
Can I buy Shanghai Cell Therapy Group stock?
Shanghai Cell Therapy Group shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Shanghai Cell Therapy Group's last funding round?
Shanghai Cell Therapy Group's most recent funding round was Series D on December 6, 2021.
Who are the main investors in Shanghai Cell Therapy Group?
Key investors in Shanghai Cell Therapy Group include Legend Capital, CCB International, Jiuzhou Venture, China Industrial Asset Management Limited, Haier Capital.
Will Shanghai Cell Therapy Group IPO soon?
No public IPO plans have been announced for Shanghai Cell Therapy Group.
How can I track Shanghai Cell Therapy Group secondary market activity?
Caplight tracks bids, offers, and trades in Shanghai Cell Therapy Group's shares on secondary markets.